You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Novel Therapies for Multiple Myeloma: Highlights for the Oncology Nurse

  • Authors: Sandra E. Kurtin, PhD, ANP-C, AOCN
  • CE Released: 10/22/2020
  • Valid for credit through: 10/22/2021
Start Activity

Target Audience and Goal Statement

This activity is intended for oncology nurses and other healthcare providers involved in the care of patients with MM.

The goal of this activity is to improve the knowledge of oncology nurses about novel and emerging therapies used to treat multiple relapsed/refractory (R/R) multiple myeloma (MM) and to improve their skills educating patients about participation in clinical trials.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Risk factors for developing R/R MM
    • Potential adverse effects of novel therapies for R/R MM
  • Have greater competence related to
    • Discussing clinical trial participation with patients with R/R MM
  • Demonstrate greater confidence in their ability to
    • Provide education about novel therapies to patients with R/R MM


As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


  • Sandra E. Kurtin, PhD, ANP-C, AOCN

    Director, Advanced Practice
    Assistant Professor of Clinical Medicine
    Assistant Professor of Nursing
    The University of Arizona Cancer Center
    Tucson, Arizona


    Disclosure: Sandra E. Kurtin, PhD, ANP-C, AOCN, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Abbvie; Amgen; AstraZeneca; Genentech; Incyte; Pharmacyclics; Takeda
    Served as a speaker or a member of a speakers bureau for: Abbvie; Amgen; AstraZeneca; Genentech; Incyte; Pharmacyclics; Takeda


  • Sara Fagerlie, PhD, CHCP

    Medical Education Director, WebMD Global, LLC


    Disclosure: Sara Fagerlie, PhD, CHCP, has disclosed no relevant financial relationships.

CE Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Novel Therapies for Multiple Myeloma: Highlights for the Oncology Nurse

Authors: Sandra E. Kurtin, PhD, ANP-C, AOCNFaculty and Disclosures

CE Released: 10/22/2020

Valid for credit through: 10/22/2021


ADC = antibody-drug conjugate
ADCC = antibody-dependent cell-mediated cytotoxicity
AE = adverse event
ASCT = autologous stem cell transplant
ASTCT = American Society for Transplantation and Cellular Therapy
BCMA = B-cell maturation antigen
BiTE® = bispecific T-cell engager
Bor = bortezomib
Car = carfilzomib
CAR T = chimeric antigen receptor T cell
CBR = clinical benefit rate
CD = cluster of differentiation
CR = complete response
CRS = cytokine release syndrome
CTCAE = Common Terminology Criteria for Adverse Events
CTEP = Cancer Therapy Evaluation Program
Ctrough = trough concentration
Cyclo = cyclophosphamide
Dara = daratumumab
DCEP = dexamethasone, cyclophosphamide, etoposide, cisplatin
del = deletion
Dex = dexamethasone
DFS = disease-free survival
DIC = disseminated intravascular coagulation
DLT = dose-limiting toxicity
DoR = duration of response
Dox = doxorubicin
DT-PACE = dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, etoposide
Elo = elotuzumab
EP = endpoint
Fc = fragment crystallizable
FISH = fluorescent in situ hybridization
Flu = fludarabine
GFR = glomerular filtration rate
GI = gastrointestinal
ICANS = immune effector cell-associated neurologic syndrome
IgG = immunoglobulin G
IL = interleukin
IMiD = immunomodulatory drug
IMP = importin
IMWG = International Myeloma Working Group
Isa = isatuximab
ISS = International Staging System
IV = intravenous
Ixa = ixazomib
LDH = lactate dehydrogenase
Len = lenalidomide
mAb = monoclonal antibody
MM = multiple myeloma
MMAF = monomethyl auristatin F
MR = minor response
MTD = maximum tolerated dose
NA = not available
NCCN = National Comprehensive Cancer Network
NK = natural killer
NPC = nuclear pore complex
ORR = overall response rate
OS = overall survival
PD = progressive disease
PFS = progression-free survival
PI = proteasome inhibitor
PJP = Pneumocystis jirovecii pneumonia
Pom = pomalidomide
PR = partial response
R = randomization
RCT = randomized controlled trial
REMS = Risk Evaluation and Mitigation Strategy
R-ISS = revised International Staging System
RRMM = relapsed/refractory multiple myeloma
SC = subcutaneous
SD = stable disease
SINE = selective inhibitor of nuclear export
t = translocation
thal = thalidomide
TTP = time to progression
ULN = upper limit of normal
VGPR = very good partial response
XPO1 = exportin 1

« Return to: Novel Therapies for Multiple Myeloma: Highlights for the Oncology Nurse
  • Print